Loading
NASDAQHealthcareMedical - Devices
Latest quote
$8.75
+$0.57 · +6.97%
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Previous close
$8.75
+$0.57 · +6.97%
After-hours
$8.59
−$0.16 · -1.83%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Day range
Current $8.75
52-week range
Current $8.75
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
31
Expensive
Sentiment
47
Mixed
Risk
72
High Risk
Momentum
35
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Day range
Current $8.75
52-week range
Current $8.75
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 528K USD | 546K USD | 525K USD | 452.91K USD |
| Gross profit | — | −528K USD | −546K USD | −525K USD | −452.91K USD |
| Research and development | 9.98M USD | 12.25M USD | 13.58M USD | 9.91M USD | 5.73M USD |
| Selling, general, and administrative | 10.92M USD | 11.05M USD | 11.11M USD | 14.49M USD | 10.71M USD |
| Operating expenses | 20.9M USD | 23.3M USD | 24.69M USD | 24.41M USD | 16.44M USD |
| Interest income | 692K USD | 389K USD | 180K USD | 161K USD | 18.71K USD |
| Depreciation and amortization | 489K USD | 528K USD | 546K USD | 525K USD | 453K USD |
| Operating income | −20.9M USD | −23.83M USD | −25.24M USD | −24.93M USD | −16.89M USD |
| Net income | −19.47M USD | −21.82M USD | −23.52M USD | −24.67M USD | −16.53M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 20, 2026 | 1:35 | — | — |
Stock split | Nov 30, 2020 | 1:25 | — | — |
Effective Jan 20, 2026
1:35
Effective Nov 30, 2020
1:25
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
